Digital Desk, Hyderabad. Bharat Biotech will conduct Phase-4 clinical trials to test the real-world effectiveness of Covaxin, that is, the vaccine’s effect in vaccinated people. According to the company, the Phase-IV trial will not only help in testing the real-world effectiveness, but also ensure that it meets all scientific and safety standards. At the same time, the company will also apply for a full license for Covaxin after the final analysis data of the Phase-3 study is received.
The Hyderabad-based vaccine maker also said that complete data from the Phase III trial
Let us inform that this statement of Bharat Biotech has come after the study in which Covaxin was said to be less effective than Covishield. Kolkata-based endocrinologist Dr Awadhesh Kumar Singh did this study comparing the immune response to Covishield and Covaxin. According to the study, Covishield is making more antibodies in the body than Covaxin. A Twitter war was also seen between Dr. Awadhesh Kumar Singh and Bharat Biotech’s Business Development Head, Ratchas Alla regarding this study. Bharat Biotech dismissed the study as unscientific and based on bias.
Significantly, there are currently three vaccines of corona in the country. Oxford University and AstraZeneca’s Covishield which is being built by Serum Institute in India. The second vaccine is Bharat Biotech’s Covaccine. The third Russian vaccine is Sputnik. In such a situation, Bharat Biotech said that vaccination is going on since mid-January and till now lakhs of doses of Covaxin have been administered. So soon we will have a reliable and huge amount of data.